Targets › SLC9A3
1 program from 1 company in 3 trials: 2 Phase 3, 1 Phase 2; Neurology, Gastroenterology, Respiratory; next expected readout Feb 2027.
Plasma membrane Na(+)/H(+) antiporter. Exchanges intracellular H(+) ions for extracellular Na(+) in 1:1 stoichiometry, playing a key role in salt and fluid absorption and pH homeostasis (By similarity). (UniProt, P48764)
Open in Phaseline: the race on SLC9A3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Ardelyx | Tenapanor Sodium/hydrogen exchanger 3 inhibitor | SLC9A3 | Phase 3 | Chronic Idiopathic Constipation (CIC); Cystic Fibrosis; Synucleinopathy | Feb 2027 |
Chronic Idiopathic Constipation (CIC) (1) Cystic Fibrosis (1) Synucleinopathy (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.